162 related articles for article (PubMed ID: 25810304)
1. Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.
Alvarez-Larrán A; Angona A; Ancochea A; García-Pallarols F; Fernández C; Longarón R; Bellosillo B; Besses C
Eur J Haematol; 2016 Jan; 96(1):83-9. PubMed ID: 25810304
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diagnostic criteria for polycythaemia vera.
Turkington RC; Arnold EC; Percy MJ; Ranaghan LA; Cuthbert RJ; McMullin MF
Hematology; 2007 Apr; 12(2):123-30. PubMed ID: 17454193
[TBL] [Abstract][Full Text] [Related]
3. Masked polycythemia vera diagnosed according to WHO and BCSH classification.
Barbui T; Thiele J; Carobbio A; Gisslinger H; Finazzi G; Rumi E; Luigia Randi M; Vannucchi AM; Gisslinger B; Müllauer L; Ruggeri M; Rambaldi A; Tefferi A
Am J Hematol; 2014 Feb; 89(2):199-202. PubMed ID: 24166817
[TBL] [Abstract][Full Text] [Related]
4. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.
Lussana F; Carobbio A; Randi ML; Elena C; Rumi E; Finazzi G; Bertozzi I; Pieri L; Ruggeri M; Palandri F; Polverelli N; Elli E; Tieghi A; Iurlo A; Ruella M; Cazzola M; Rambaldi A; Vannucchi AM; Barbui T
Br J Haematol; 2014 Nov; 167(4):541-6. PubMed ID: 25130523
[TBL] [Abstract][Full Text] [Related]
5. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
7. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
Gangat N; Strand J; Lasho TL; Finke CM; Knudson RA; Pardanani A; Li CY; Ketterling RP; Tefferi A
Eur J Haematol; 2008 Mar; 80(3):197-200. PubMed ID: 18081705
[TBL] [Abstract][Full Text] [Related]
9. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
10. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
Barbui T; Thiele J; Carobbio A; Guglielmelli P; Rambaldi A; Vannucchi AM; Tefferi A
Am J Hematol; 2014 Jun; 89(6):588-90. PubMed ID: 24535932
[TBL] [Abstract][Full Text] [Related]
11. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
12. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
13. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
14. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
15. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
16. Masked polycythemia vera (mPV): results of an international study.
Barbui T; Thiele J; Gisslinger H; Finazzi G; Carobbio A; Rumi E; Luigia Randi M; Bertozzi I; Vannucchi AM; Pieri L; Carrai V; Gisslinger B; Müllauer L; Ruggeri M; Rambaldi A; Tefferi A
Am J Hematol; 2014 Jan; 89(1):52-4. PubMed ID: 23996471
[TBL] [Abstract][Full Text] [Related]
17. A CBC algorithm combined with immature platelet fraction is able to identify JAK2 V617F mutation-positive polycythaemia vera patients.
Johnson S; Baker B
Int J Lab Hematol; 2019 Apr; 41(2):271-276. PubMed ID: 30601597
[TBL] [Abstract][Full Text] [Related]
18. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A; Kerguelen A; Hernández-Boluda JC; Pérez-Encinas M; Ferrer-Marín F; Bárez A; Martínez-López J; Cuevas B; Mata MI; García-Gutiérrez V; Aragües P; Montesdeoca S; Burgaleta C; Caballero G; Hernández-Rivas JA; Durán MA; Gómez-Casares MT; Besses C;
Br J Haematol; 2016 Mar; 172(5):786-93. PubMed ID: 26898196
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
[TBL] [Abstract][Full Text] [Related]
20. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]